These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 9269642)

  • 21. Bixalomer, a novel phosphate binder with a small swelling index, improves hyperphosphatemia in chronic kidney disease rat.
    Taniguchi K; Kakuta H
    Eur J Pharmacol; 2015 Nov; 766():129-34. PubMed ID: 26452517
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Results of a randomized crossover study comparing once-daily and thrice-daily sevelamer dosing.
    Fischer D; Cline K; Plone MA; Dillon M; Burke SK; Blair AT
    Am J Kidney Dis; 2006 Sep; 48(3):437-44. PubMed ID: 16931217
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sevelamer hydrochloride, a phosphate binder, protects against deterioration of renal function in rats with progressive chronic renal insufficiency.
    Nagano N; Miyata S; Obana S; Kobayashi N; Fukushima N; Burke SK; Wada M
    Nephrol Dial Transplant; 2003 Oct; 18(10):2014-23. PubMed ID: 13679475
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of phosphonoformic acid and renagel on renal type IIa sodium-dependent phosphate cotransporter mRNA expression in hyperphosphatemia rats.
    Zeng M; Wang X; Wang X; Zhao X
    Ren Fail; 2012; 34(3):358-63. PubMed ID: 22260362
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of sevelamer hydrochloride as an oxalate binder.
    Lieske JC; Regnier C; Dillon JJ
    J Urol; 2008 Apr; 179(4):1407-10. PubMed ID: 18289565
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
    Van Buren PN; Lewis JB; Dwyer JP; Greene T; Middleton J; Sika M; Umanath K; Abraham JD; Arfeen SS; Bowline IG; Chernin G; Fadem SZ; Goral S; Koury M; Sinsakul MV; Weiner DE;
    Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of sevelamer in achieving the kidney disease outcomes quality initiative (K/DOQI) guidelines for hyperphosphatemia.
    Pai AB; Smeeding JE; Brook RA
    Curr Med Res Opin; 2004 Jul; 20(7):991-9. PubMed ID: 15265243
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients.
    Chertow GM; Burke SK; Dillon MA; Slatopolsky E
    Nephrol Dial Transplant; 1999 Dec; 14(12):2907-14. PubMed ID: 10570096
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Does concomitant administration of sevelamer and calcium carbonate modify the control of phosphatemia?
    Ouellet G; Cardinal H; Mailhot M; Ste-Marie LG; Roy L
    Ther Apher Dial; 2010 Apr; 14(2):172-7. PubMed ID: 20438539
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The crossover comparative trial of calcium acetate versus sevelamer hydrochloride (Renagel) as phosphate binders in dialysis patients.
    Fournier A; Oprisiu R; Albu AT; Dungaciu M; El Esper N; Mornière P
    Am J Kidney Dis; 2000 Jun; 35(6):1248-50. PubMed ID: 10877727
    [No Abstract]   [Full Text] [Related]  

  • 32. Oral phosphate binders: phosphate binding capacity of iron (III) hydroxide complexes containing saccharides and their effect on the urinary excretion of calcium and phosphate in rats.
    Yamaguchi T; Baxter JG; Maebashi N; Asano T
    Ren Fail; 1999 Sep; 21(5):453-68. PubMed ID: 10516989
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term comparison of sevelamer hydrochloride to calcium-containing phosphate binders.
    Brewster UC; Ciampi MA; Abu-Alfa AK; Reilly RF
    Nephrology (Carlton); 2006 Apr; 11(2):142-6. PubMed ID: 16669977
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of iron(III) chitosan intake on the reduction of serum phosphorus in rats.
    Baxter J; Shimizu F; Takiguchi Y; Wada M; Yamaguchi T
    J Pharm Pharmacol; 2000 Jul; 52(7):863-74. PubMed ID: 10933138
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of hyperphosphataemia in dialysis patients: role of phosphate binders in the elderly.
    Lorenzo Sellares V; Torres Ramírez A
    Drugs Aging; 2004; 21(3):153-65. PubMed ID: 14979734
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.
    Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP
    Clin Nephrol; 1996 Feb; 45(2):111-9. PubMed ID: 8846523
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients.
    Shaheen FA; Akeel NM; Badawi LS; Souqiyyeh MZ
    Saudi Med J; 2004 Jun; 25(6):785-91. PubMed ID: 15195212
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improving phosphate-binder therapy as a way forward.
    Hutchison AJ
    Nephrol Dial Transplant; 2004 Mar; 19 Suppl 1():i19-24. PubMed ID: 15126650
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
    Navaneethan SD; Palmer SC; Craig JC; Elder GJ; Strippoli GF
    Am J Kidney Dis; 2009 Oct; 54(4):619-37. PubMed ID: 19692157
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.